Albireo Pharma




MarketCap US

US United States


Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.


Founded in 2007, Albireo is a specialized biopharmaceutical company focused on the development of novel bile acid modulators to treat rare diseases. The company is dedicated to transforming the lives of patients with liver and gastrointestinal diseases through pioneering scientific innovation.

Albireo’s mission is to bring life-changing treatments to people living with rare diseases.

Albireo’s vision is to become the leader in the discovery and development of bile acid modulators for rare diseases through innovative science and customer-focused collaborations.

Key Team

Dr. Per-Goran Gillberg Ph.D. (Co-Founder & VP of Devel.)

Dr. Jan P. Mattsson Ph.D. (Chief Scientific Officer, MD (Sweden) & Co-Founder)

Ms. Joan Connolly (Chief Technology Officer)

Mr. Jason G. Duncan (Chief Legal Officer, Gen. Counsel & Sec.)

Ms. Michelle Graham (Chief HR Officer)

Dr. Kristina Torfgard (VP & Global Project Head)

Ms. Pamela Stephenson M.P.H. (Chief Commercial Officer)

Recognition and Awards
The company has won several awards for its commitment to innovation, including the Parenteral Drug Association’s Innovation Award, the Scrip Awards, and the Entrepreneur of the Year award.

Albireo Pharma
Leadership team

Mr. Ronald H. W. Cooper (CEO, Pres & Director)

Mr. Simon Nicolas Reade Harford (CFO & Treasurer)

Ms. Martha J. Carter (Chief Regulatory Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Gothenburg, Vastra Gotaland, Sweden
Company Registration
SEC CIK number: 0001322505
20M - 100M
Traded as
Social Media
Sun Mar 03 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium